The Latest ‘Word’ on Neurodegenerative Diseases
Dr. Benjamin Wolozin
April 9, 2023
Dr. Benjamin Wolozin is at Boston University School of Medicine. His talk was titled “The Latest ‘Word’ on Neurodegenerative Diseases,” focusing mainly in Alzheimer’s – its biology, diagnosis, and treatment.
He began by noting that normal aging entails a gradual decline in cognition; and while short term memory may suffer, long term memory remains intact. (He used the word “amnestic” as applicable to mild cognitive impairment.) Alzheimer’s is a pretty precipitate fall, with loss of “executive function” and complex thinking. But it involves physical brain changes detectable twenty years before such symptoms emerge.
Alzheimer’s is a source of dementia, characterized by formation of clumps or tangles of beta-amyloid plaques in the brain. But that’s not the whole story, and while beta-amyloids may start the process, other factors are quite important in the progression.
Wolozin went through them. Heart health, he said, equals brain health. “Vasculature” delivers oxygen to the brain, and beta-amyloids can accumulate in blood vessels, slowing blood flow. Blood pressure, cholesterol, and exercise levels are all part of the picture.
Good diet and a normal body mass index play a role; as do social relationships. Inflammation, said Wolozin, is “super important” too.
In short, people with overall healthy lifestyles are less vulnerable to Alzheimer’s. Some can have beta-amyloid plaques without ill effects. And then there’s genetics – if your parents had Alzheimer’s, watch out.
But there are various sources of dementia, it’s not all Alzheimer’s, with some varieties more treatable than others. And medicine is getting pretty good at such diagnosis, detecting brain etiologies like beta-amyloids using imaging techniques, and also blood or spinal fluid tests.
For several decades there have been medicines to treat the symptoms, but not very effectively, slowing cognitive decline only slightly. More recently there was a controversy about Aduhelm, FDA-approved, with questions about its likewise limited effectiveness in relation to its considerable cost. But Dr. Wolozin was more positive about an even newer medicine, lecanamab, which he thinks workers better.
He also spoke about Parkinson’s Disease – what accumulates in the brain there is alpha-synuclein. This makes dopamine neurons die. Treatment involves reducing alpha-synuclein and increasing dopamine.
Wolozin concluded with some remarks about aging in general, relating a conversation with his wife in which he suggested they just stop doing it. Surely sound medical advice.